Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Gilead’s Yeztugo Sales “Ahead of Expectations” Following Launch

Summary by Pharmaceutical-technology.com
Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

GeneOnline NewsGeneOnline News

Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031

Gilead Sciences’ newly launched HIV prevention drug, Ye […] The post Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 first appeared on GeneOnline News. The post Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 appeared first on GeneOnline News.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Gilead’s Yeztugo sales “ahead of expectations” following launch

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Friday, August 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Gilead Sciences icon

Gilead Sciences

News
For You
SearchBlindspotLocal